IDAVANG A/S financials
IDAVANG A/S
5493000WVOJNMTISMP12 | Line item | 2023 | 2022 |
|---|---|---|
| Income statement | ||
| Revenue | €142.3M | €115.2M |
| Cost of sales | €135.3M | €104.7M |
| Other income | €2.4M | €7.6M |
| Administrative expenses | €4.3M | €4.3M |
| Operating profit (EBIT) | €11.6M | €22.3M |
| Finance costs | €7.0M | €7.3M |
| Profit before tax | €5.1M | €18.4M |
| Income tax expense | €4.3M | €2.7M |
| Profit for the year | €792.0K | €15.7M |
| — attributable to owners | €792.0K | €15.7M |
| Total comprehensive income | -€18.1M | €22.0M |
| Cash flow statement | ||
| Cash generated from operations | €35.9M | €24.1M |
| Net cash from operating activities | €28.7M | €17.8M |
| Income taxes paid | €827.0K | -€220.0K |
| Net cash from investing activities | -€1.9M | -€6.8M |
| Purchase of PP&E (capex) | €1.9M | €4.4M |
| Purchase of intangibles | €0 | €5.0K |
| Net cash from financing activities | -€18.5M | -€15.0M |
| Dividends paid | €0 | €0 |
| Proceeds from borrowings | €2.8M | €11.6M |
| Repayments of borrowings | €21.3M | €26.6M |
| Net change in cash | €8.4M | -€4.0M |
| Balance sheet | ||
| Total assets | €121.4M | €158.4M |
| Non-current assets | €56.9M | €96.8M |
| Property, plant & equipment | €40.3M | €80.9M |
| Intangible assets & goodwill | €1.0M | €1.2M |
| Current assets | €64.5M | €61.5M |
| Inventories | €10.5M | €17.4M |
| Trade & other receivables | €4.1M | €3.5M |
| Cash & equivalents | €17.5M | €10.0M |
| Total equity | €43.6M | €61.7M |
| Non-current liabilities | €58.4M | €63.9M |
| Long-term borrowings | €52.5M | €58.7M |
| Current liabilities | €19.4M | €32.7M |
| Deferred tax liabilities | €4.0M | €3.0M |
| Derived metrics | ||
| Free cash flow | €26.9M | €13.4M |
| Operating margin | 8.2% | 19.3% |
| Net margin | 0.6% | 13.7% |
| Return on equity | 1.8% | 25.5% |
| Cash conversion ratio | 36.30× | 1.13× |
| Capex coverage | 15.16× | 4.05× |
| Other reported items | ||
| Adjustments For Decrease Increase In Biological Assets | -€1.1M | -€1.7M |
| Adjustments For Decrease Increase In Inventories | €3.7M | -€1.0M |
| Adjustments For Decrease Increase In Trade and Other Receivables | €77.0K | €1.7M |
| Adjustments For Depreciation and Amortisation Expense | €33.7M | €8.0M |
| Adjustments For Gain Loss On Disposals Property Plant and Equipment | €0 | €37.0K |
| Adjustments For Gains Losses On Change In Fair Value Less Costs To Sell Biological Assets | €6.6M | €8.4M |
| Adjustments For Increase Decrease In Other Current Liabilities | €80.0K | €388.0K |
| Adjustments For Increase Decrease In Trade and Other Payables | -€786.0K | €2.4M |
| Bank Overdrafts Classified As Cash Equivalents | €9.0M | €9.0M |
| Cash | €17.5M | €10.0M |
| Current Advances | €1.3M | €829.0K |
| Current Biological Assets | €30.9M | €27.9M |
| Current Loans Received and Current Portion of Noncurrent Loans Received | €3.2M | €17.7M |
| Current Prepayments | €716.0K | €692.0K |
| Current Tax Assets Current | €347.0K | €392.0K |
| Current Tax Liabilities Current | €3.2M | €745.0K |
| Deferred Tax Assets | €759.0K | €761.0K |
| Effect of Exchange Rate Changes On Cash and Cash Equivalents | -€839.0K | €461.0K |
| Equity and Liabilities | €121.4M | €158.4M |
| Finance Income | €507.0K | €3.5M |
| Gains Losses On Cash Flow Hedges Net of Tax | €0 | €4.9M |
| Gains Losses On Fair Value Adjustment Biological Assets | €6.6M | €8.4M |
| Interest Paid Classified As Operating Activities | €6.8M | €7.1M |
| Interest Received Classified As Operating Activities | €458.0K | €458.0K |
| Issued Capital | €800.0K | €800.0K |
| Liabilities | €77.8M | €96.7M |
| Noncurrent Biological Assets | €14.4M | €13.5M |
| Noncurrent Financial Assets | €444.0K | €445.0K |
| Noncurrent Government Grants | €1.5M | €1.7M |
| Noncurrent Provisions | €0 | €0 |
| Other Comprehensive Income Net of Tax Exchange Differences On Translation | -€14.0M | €5.6M |
| Other Comprehensive Income That Will Be Reclassified To Profit Or Loss Net of Tax | -€18.9M | €6.2M |
| Other Comprehensive Income That Will Not Be Reclassified To Profit Or Loss Net of Tax | €0 | €0 |
| Other Current Payables | €4.0M | €3.7M |
| Other Current Receivables | €527.0K | €1.7M |
| Other Expense By Function | €0 | €0 |
| Other Noncurrent Assets | €1.2M | €1.2M |
| Other Noncurrent Liabilities | €348.0K | €554.0K |
| Other Reserves | €0 | €4.9M |
| Proceeds From Sales of Property Plant and Equipment Classified As Investing Activities | €317.0K | €133.0K |
| Purchase of Investments Other Than Investments Accounted For Using Equity Method | €0 | €0 |
| Reclassification Adjustments On Cash Flow Hedges Net of Tax | €4.9M | €4.3M |
| Reserve of Exchange Differences On Translation | -€43.2M | -€29.2M |
| Retained Earnings | €86.0M | €85.2M |
| Trade and Other Current Payables To Trade Suppliers | €7.8M | €9.7M |
Every line item above is a fact tagged in IDAVANG A/S's annual report
filed in the European Single Electronic Format (ESEF) under the IFRS
taxonomy (ifrs-full) — the income statement, balance sheet
and cash-flow statement as the filer reported them. Values are shown
as-is, in the reporting currency (EUR), without
rescaling; the row labels map to the underlying concept name (e.g.
Revenue → ifrs-full:Revenue, Operating profit →
ifrs-full:ProfitLossFromOperatingActivities, Diluted EPS →
ifrs-full:DilutedEarningsLossPerShare), and any concept
without a curated label is shown under “Other reported items” with its
de-camel-cased tag name. Only consolidated, default-member facts are
shown (segment / dimensional breakdowns are excluded).
“Derived metrics” (free cash flow, margins, ROE, …) are computed from those facts by the same model the U.S. financials pages use — not tagged by the filer.
Source: machine-readable OIM xBRL-JSON aggregated by filings.xbrl.org (XBRL International). Entity identity is resolved by LEI via the public-domain GLEIF register. This is reference data, not investment advice.